Niaspan buyers denied class cert

A federal judge in Pennsylvania has rejected a bid for class certification by end-purchasers of cholesterol medication Niaspan in their lawsuit against drugmakers AbbVie and Teva Pharmaceuticals.


Get unlimited access to all Global Competition Review content